114 related articles for article (PubMed ID: 25022069)
1. [Companion diagnostics with FISH assay (HER2, ALK)].
Hiraoka M
Rinsho Byori; 2014 Apr; 62(4):390-8. PubMed ID: 25022069
[TBL] [Abstract][Full Text] [Related]
2. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
3. Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
van der Wekken AJ; Pelgrim R; 't Hart N; Werner N; Mastik MF; Hendriks L; van der Heijden EHFM; Looijen-Salamon M; de Langen AJ; Staal-van den Brekel J; Riemersma S; van den Borne BE; Speel EJM; Dingemans AC; Hiltermann TJN; van den Berg A; Timens W; Schuuring E; Groen HJM
Clin Cancer Res; 2017 Aug; 23(15):4251-4258. PubMed ID: 28183714
[No Abstract] [Full Text] [Related]
4. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
6. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
[TBL] [Abstract][Full Text] [Related]
7. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
8. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).
Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496
[TBL] [Abstract][Full Text] [Related]
9. [Companion diagnostics in the era of personalized medicine--chairmen's introductory remarks].
Fukutsuka K; Takubo T
Rinsho Byori; 2014 Apr; 62(4):378-80. PubMed ID: 25022067
[TBL] [Abstract][Full Text] [Related]
10. Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
Selinger C; Cooper W; Lum T; McNeil C; Morey A; Waring P; Amanuel B; Millward M; Peverall J; Van Vliet C; Christie M; Tran Y; Diakos C; Pavlakis N; Gill AJ; O'Toole S
Histopathology; 2015 Nov; 67(5):654-63. PubMed ID: 25847523
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
Francz M; Egervari K; Kardos L; Toth J; Nemes Z; Szanto J; Szollosi Z
J Clin Pathol; 2010 Apr; 63(4):341-6. PubMed ID: 19965795
[TBL] [Abstract][Full Text] [Related]
13. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
14. Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study.
Zwaenepoel K; Merkle D; Cabillic F; Berg E; Belaud-Rotureau MA; Grazioli V; Herelle O; Hummel M; Le Calve M; Lenze D; Mende S; Pauwels P; Quilichini B; Repetti E
Exp Mol Pathol; 2015 Feb; 98(1):113-8. PubMed ID: 25576649
[TBL] [Abstract][Full Text] [Related]
15. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
17. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
18. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
19. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826
[TBL] [Abstract][Full Text] [Related]
20. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
